• Atox Bio Ltd., of Ness Ziona, Israel, reported top-line results from a Phase IIa trial showing that AB103, a short peptide immune regulatory therapy, produced meaningful improvement across multiple endpoints vs. placebo in patients with necrotizing soft-tissue infections. Read More
• NeoStem Inc., of New York, said it was awarded a two-year grant totaling $1.2 million to study the repair of bone defects with human autologous pluripotent very small embryonic-like (VSEL) stem cells from the National Institute of Dental and Craniofacial Research. Read More
A pair of new reports on the pharmaceutical industry portrays a mixed bag of opportunity and challenge as the global giants wrestle with fragmented marketplaces, stagnating management cultures, shrinking pipelines and growing price controls. Read More
Vaccines are among the greatest public health triumphs ever. But they do not work equally well for all infectious diseases. "There are certain diseases which we have had a hard time controlling," Nimalan Arinaminpathy told BioWorld Today. Read More
According to the SEC, an insider trading ring based out of Celgene Corp., Sanofi SA and Stryker Corp. was counting on a lack of resources for enforcement at the agency to evade discovery. Those hopes were dashed Monday. Read More
After years of throwing themselves futilely against the beta amyloid wall, companies trying for Alzheimer's disease (AD) therapies are turning away, hoping to find a door that opens on a way to modify the devastating condition. Read More
• Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the European Commission approved Eliquis (apixaban) for prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation with one or more risk factors. Read More
